ASRS 39th Annual Scientific Meeting: A review of findings reported
October 13, 2021
A review of studies, presentations and discussions at ASRS 2021 in San Antonio, Texas.
© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
Retina
Investigative antibody shows sustained efficacy in retinal disease studies
October 18, 2021
Results from Phase 3 trials of bispecific antibody faricimab demonstrate that it is more durable than currently available agents, and it has a good safety profile.
Chronic non-infectious posterior uveitis: Dissecting real-world registry study of YUTIQ
October 12, 2021
Dr Ankur Shah discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
Retina industry insights from Alcon on display at Ophthalmology Innovation Summit
October 12, 2021
Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.
Intravitreal pegcetacoplan proves useful for geographic atrophy: Phase 3 results of OAKS and DERBY studies
October 11, 2021
At ASRS 2021, Dr David Boyer reported that pegcetacoplan used to treat geographic atrophy and administered in monthly or every-other-month regimens was well tolerated in patients in the phase 3 DERBY and OAKS studies.
PDS with ranibizumab in nAMD offers similar results to ranibizumab monthly injections
October 11, 2021
Dr Arshad Khanani reported at ASRS 2021 that the Port Delivery System with ranibizumab, an investigational product that continuously delivers ranibizumab intravitreally, achieved results similar to those in patients treated with monthly ranibizumab injections for nAMD.
Using commercial OCT to track macrophages in the macular circulation
October 10, 2021
At ASRS 2021 in San Antonio, TX, Dr Richard B. Rosen reported that clinical optical coherence tomography (OCT) can image and measure macular surface macrophage cells.
HAWK study: Higher order OCT analysis for inflammatory signal biomarkers
October 10, 2021
Dr Justis P. Ehlers discusses the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.
Universal masking may lower risk of endophthalmitis after intravitreal anti-VEGF injections
October 10, 2021
During the ASRS Annual Scientific Meeting, Dr Sunir Garg reported that the risk of presumed infectious endophthalmitis following administration of anti-VEGF injections does not increase and universal masking may actually decrease the risk of culture-positive endophthalmitis.
The relationship between MIGS procedures and endophthalmitis
October 10, 2021
At the ASRS 39th Annual Scientific Meeting, Dr Yoshihiro Yonekawa reported that the prevalence of endophthalmitis following MIGS is similar to the prevalence rates of endophthalmitis after other incisional glaucoma surgeries.